Forty sexually active HIV-negative American women between the ages of 18 and 24 are participating in a two-week trial to test the effectiveness of VivaGel, a vaginal microbicide gel for preventing transmission of HIV and genital herpes. The gel is being tested for safety and ease of use, according to its Australian maker, Starpharma Holdings, Inc.